Testosterone Cypionate and Pregabalin Interaction: Safety, Risks, and Monitoring

Why These Two Drugs Are Frequently Co-Prescribed

Men receiving testosterone replacement therapy (TRT) for hypogonadism often carry comorbid conditions that pregabalin treats, including neuropathic pain, fibromyalgia, and generalized anxiety disorder. The 2018 Endocrine Society Clinical Practice Guideline estimates that 2-6% of adult men meet criteria for testosterone deficiency, with prevalence rising sharply after age 45 [1]. Pregabalin (brand name Lyrica), meanwhile, ranked among the 100 most-prescribed medications in the United States prior to generic entry, with over 10 million annual prescriptions reported by IQVIA in 2019 [2].

Overlap is common. A 2020 Veterans Affairs pharmacy cohort study found that roughly 18% of men on long-term TRT also received at least one gabapentinoid prescription within the same 12-month period [3]. Clinicians and patients reasonably ask whether combining these medications introduces hidden risks. The short answer: the pharmacokinetic profiles do not collide, but shared side effects require proactive monitoring.

Pharmacokinetic Analysis: No Metabolic Collision

Testosterone cypionate is an intramuscular depot formulation. After injection, esterases in the blood cleave the cypionate ester, releasing free testosterone. The hormone then undergoes hepatic biotransformation primarily through CYP3A4 and, to a lesser extent, CYP2C9 and CYP2C19 [4]. Testosterone also serves as a substrate for 5-alpha reductase (producing dihydrotestosterone) and aromatase (producing estradiol).

Pregabalin follows a completely separate elimination pathway. According to the FDA-approved Lyrica prescribing information, pregabalin undergoes negligible metabolism in humans [5]. Approximately 98% of an oral dose is recovered unchanged in urine. The drug is not bound to plasma proteins. It does not inhibit or induce any known CYP isoenzyme, and it is not a substrate or inhibitor of P-glycoprotein.

This means there is zero expected competition at the CYP3A4, CYP2C9, or P-gp level. Testosterone will not raise pregabalin concentrations. Pregabalin will not lower or raise testosterone levels. No dose adjustment for either drug is warranted based on coadministration alone.

Pharmacodynamic Overlap: Edema, Weight, and CNS Effects

The real clinical conversation centers on pharmacodynamic additivity, where both drugs independently produce similar adverse effects that may worsen when combined.

Peripheral Edema

The Lyrica prescribing information reports peripheral edema in 6% of patients at 150 mg/day, rising to 16% at 600 mg/day [5]. The Depo-Testosterone FDA label lists fluid retention as a recognized adverse reaction, particularly in patients with pre-existing cardiac, renal, or hepatic compromise [6]. Testosterone promotes sodium and water retention through activation of the renin-angiotensin-aldosterone system and direct tubular effects [7].

When both drugs are on board, the risk of clinically significant lower-extremity swelling rises. This is especially relevant for patients with congestive heart failure (NYHA Class III-IV), where the Endocrine Society guideline advises against initiating testosterone therapy [1].

Weight Gain

Pregabalin-associated weight gain averages 1.5-3.5 kg over 12 weeks in clinical trials, with up to 14% of patients in fibromyalgia studies gaining more than 7% of baseline body weight [5]. Testosterone therapy, by contrast, typically reduces fat mass and increases lean mass. A meta-analysis of 32 RCTs (N=4,513) published in Endocrine Reviews found that testosterone treatment reduced total body fat by a mean of 1.6 kg while increasing lean body mass by 1.6 kg [8]. These opposing metabolic vectors may partially offset one another, but clinicians should still track weight trends because pregabalin-driven fat accumulation can mask testosterone's favorable body-composition effects.

CNS and Mood Effects

Pregabalin produces dose-dependent somnolence (reported in 15-25% of patients across indications) and dizziness (up to 38% in epilepsy add-on trials) [5]. Testosterone cypionate does not carry a direct sedation signal, but supraphysiologic levels may cause irritability, mood instability, or sleep disruption [6]. Conversely, restoration of eugonadal testosterone levels often improves energy, mood, and cognitive clarity. The net CNS picture depends heavily on testosterone dosing precision. Keeping trough levels within the 400-700 ng/dL reference window recommended by the Endocrine Society minimizes mood-related side effects [1].

Hematologic Monitoring: Polycythemia Remains a Testosterone-Specific Risk

Pregabalin does not affect red blood cell production. Testosterone, on the other hand, stimulates erythropoiesis through both direct bone-marrow effects and suppression of hepcidin [9]. The TTrials (Testosterone Trials, N=790) found that men receiving 1% testosterone gel had a 3.5-fold higher incidence of hematocrit exceeding 54% compared to placebo over 12 months [10].

A hematocrit above 54% substantially increases venous thromboembolism and stroke risk. The Endocrine Society recommends checking hematocrit at baseline, at 3-6 months after initiation, and annually thereafter [1]. This monitoring schedule does not change when pregabalin is added, but providers should not allow the absence of a pharmacokinetic interaction to lull them into skipping routine labs.

Renal Function: The Variable That Changes Pregabalin Dosing

Because pregabalin is eliminated almost exclusively by glomerular filtration, any decline in renal function directly raises pregabalin plasma concentrations. The Lyrica label specifies dose reductions when creatinine clearance (CrCl) falls below 60 mL/min, with further reductions at CrCl <30 mL/min and <15 mL/min [5].

Testosterone itself is not directly nephrotoxic. A population-based cohort study of 10,583 hypogonadal men in Sweden found no increased incidence of chronic kidney disease with testosterone therapy over a median follow-up of 5.2 years [11]. Still, testosterone-driven fluid retention and potential blood-pressure elevation can theoretically stress borderline kidneys. Clinicians prescribing both agents should obtain a baseline estimated GFR, repeat it at 6-12 months, and recalculate the pregabalin dose if renal function changes.

Abuse and Dependence Considerations

Pregabalin carries a DEA Schedule V classification. Post-marketing surveillance in Europe identified misuse rates between 1.6% and 12.1% depending on the population studied, with higher rates among individuals with a history of substance use disorder [12]. The European Medicines Agency safety review prompted updated labeling to warn of abuse potential, particularly when combined with opioids or benzodiazepines.

Testosterone cypionate is a Schedule III controlled substance due to its anabolic properties. Co-prescribing two controlled substances requires clear documentation of clinical necessity. Neither drug potentiates the euphoric effects of the other through a known pharmacologic mechanism, but comprehensive medication reconciliation remains good practice.

Practical Monitoring Protocol for Dual Use

A structured follow-up plan reduces the chance of overlooked adverse effects.

Before starting both drugs together:

• Obtain baseline hematocrit, hemoglobin, PSA, lipid panel, hepatic panel, serum creatinine with eGFR, and body weight.
• Assess lower-extremity edema using a standardized 0-4 pitting scale.
• Document baseline pain scores if pregabalin is prescribed for neuropathy.

At 4-6 weeks:

• Check for new or worsening peripheral edema.
• Reassess somnolence, dizziness, and mood. If pregabalin-related sedation is significant, verify testosterone trough level to rule out supraphysiologic dosing compounding fatigue.
• Repeat body weight.

At 3 months:

• Repeat hematocrit and total testosterone trough.
• Repeat serum creatinine if baseline eGFR was <60 mL/min/1.73 m².
• Recalculate pregabalin dose if renal function has shifted.

Every 6-12 months ongoing:

• Hematocrit, PSA, testosterone trough, lipid panel.
• Edema assessment, weight trend, mood screening.

When to Reconsider the Combination

Most patients tolerate both medications without complications. Specific scenarios warrant reassessment:

If peripheral edema reaches grade 2 or higher (visible swelling that partially resolves with elevation), consider lowering pregabalin before adjusting testosterone, because pregabalin's edema signal is dose-dependent and more readily titratable. Gabapentin may be a reasonable alternative with a somewhat lower edema incidence [13].

If hematocrit exceeds 54%, reduce the testosterone cypionate dose or extend the injection interval from every 7 days to every 10-14 days. Pregabalin is not contributing to this problem and does not need adjustment.

If the patient develops unexplained rapid weight gain exceeding 3 kg over 4 weeks, check for fluid retention first (BNP, echocardiogram if clinically indicated) before attributing it to pregabalin's metabolic effects alone.

Counseling Points for Patients

Patients should know three things. First, these two medications do not interfere with each other's absorption or breakdown. Taking them on the same day or at the same time is not a problem from a drug-metabolism standpoint.

Second, swelling in the ankles or feet is the most likely overlapping side effect. Patients should report new puffiness rather than assuming it is benign. Third, pregabalin can cause drowsiness, especially during the first two weeks or after dose increases. Alcohol amplifies this effect. Testosterone does not add sedation directly, but poor sleep from suboptimal testosterone dosing can make daytime drowsiness feel worse.

Patients using pregabalin for neuropathic pain should track their pain scores at home. A validated tool like the Brief Pain Inventory takes less than five minutes and gives the prescriber objective data at each follow-up visit [14].